| scholarly article | Q13442814 |
| P50 | author | Marit Otterlei | Q28718102 |
| Siver Andreas Moestue | Q42637173 | ||
| Tone F. Bathen | Q61104171 | ||
| Jana Kim | Q117273951 | ||
| P2093 | author name string | Siri Bachke | |
| Deborah K Hill | |||
| Morten B Rye | |||
| Nina-Beate Liabakk | |||
| Anala Nepal | |||
| Caroline K Søgaard | |||
| P2860 | cites work | Nucleotide excision repair is associated with the replisome and its efficiency depends on a direct interaction between XPA and PCNA | Q21133901 |
| Proliferating cell nuclear antigen in the cytoplasm interacts with components of glycolysis and cancer | Q24300118 | ||
| GADD34 induces p53 phosphorylation and p21/WAF1 transcription | Q24300442 | ||
| Identification of SNF1/AMP kinase-related kinase as an NF-kappaB-regulated anti-apoptotic kinase involved in CD95-induced motility and invasiveness | Q24302467 | ||
| NuSAP, a novel microtubule-associated protein involved in mitotic spindle organization | Q24321485 | ||
| Polyubiquitinated PCNA recruits the ZRANB3 translocase to maintain genomic integrity after replication stress | Q24338351 | ||
| Proliferating cell nuclear antigen acts as a cytoplasmic platform controlling human neutrophil survival | Q24595974 | ||
| The helicase FBH1 is tightly regulated by PCNA via CRL4(Cdt2)-mediated proteolysis in human cells | Q24599645 | ||
| Identification of a novel, widespread, and functionally important PCNA-binding motif | Q24656594 | ||
| A mouse stromal response to tumor invasion predicts prostate and breast cancer patient survival | Q27303204 | ||
| Global cancer statistics, 2012 | Q27860501 | ||
| Evidence of cancer-promoting roles for AMPK and related kinases | Q28083964 | ||
| PCNA: a silent housekeeper or a potential therapeutic target? | Q28236494 | ||
| Inhibition of p21-activated kinase 6 (PAK6) increases radiosensitivity of prostate cancer cells | Q28269570 | ||
| Distinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcome | Q28273187 | ||
| PCNA binding through a conserved motif | Q28274063 | ||
| Regulation of PCNA-protein interactions for genome stability | Q28289142 | ||
| PCNA, the maestro of the replication fork | Q28303101 | ||
| The transcription factor TFII-I promotes DNA translesion synthesis and genomic stability | Q28539614 | ||
| The S-nitrosylation status of PCNA localized in cytosol impacts the apoptotic pathway in a Parkinson's disease paradigm | Q28543412 | ||
| Increased smad expression and activation are associated with apoptosis in normal and malignant prostate after castration | Q28583522 | ||
| Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial | Q29620155 | ||
| The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation | Q30436561 | ||
| Diffusion-weighted MRI for early detection and characterization of prostate cancer in the transgenic adenocarcinoma of the mouse prostate model. | Q31021726 | ||
| Cellular retinoic acid-binding protein 2 is down-regulated in prostate cancer. | Q33224764 | ||
| Novel interaction between proliferating cell nuclear antigen and HLA I on the surface of tumor cells inhibits NK cell function through NKp44. | Q33292470 | ||
| Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44. | Q33292532 | ||
| Methylation screening of the TGFBI promoter in human lung and prostate cancer by methylation-specific PCR. | Q33373839 | ||
| Multivariate gene expression analysis reveals functional connectivity changes between normal/tumoral prostates | Q33389634 | ||
| DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells | Q33805578 | ||
| Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC). | Q33836807 | ||
| Caffeic acid phenethyl ester causes p21 induction, Akt signaling reduction, and growth inhibition in PC-3 human prostate cancer cells | Q34162761 | ||
| Prostate cancer in a transgenic mouse | Q34444393 | ||
| Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells | Q34922853 | ||
| Increased Anticancer Efficacy of Intravesical Mitomycin C Therapy when Combined with a PCNA Targeting Peptide | Q35028770 | ||
| Identification and validation of potential new biomarkers for prostate cancer diagnosis and prognosis using 2D-DIGE and MS. | Q35033878 | ||
| EPLIN downregulation promotes epithelial-mesenchymal transition in prostate cancer cells and correlates with clinical lymph node metastasis | Q35190722 | ||
| Cell lines used in prostate cancer research: a compendium of old and new lines--part 1. | Q36005681 | ||
| Ly6E/K Signaling to TGFβ Promotes Breast Cancer Progression, Immune Escape, and Drug Resistance | Q37012226 | ||
| From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. | Q37090054 | ||
| A functional analysis of PCNA-binding peptides derived from protein sequence, interaction screening and rational design | Q37236371 | ||
| Synthetic lethality screen identifies RPS6KA2 as modifier of epidermal growth factor receptor activity in pancreatic cancer | Q37448070 | ||
| Biomarkers for prostate cancer: present challenges and future opportunities | Q37474443 | ||
| Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies | Q37619763 | ||
| Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer | Q38126220 | ||
| EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. | Q38169849 | ||
| IFN-gamma enhances TRAIL-induced apoptosis through IRF-1. | Q38334935 | ||
| Jumonji histone demethylases as emerging therapeutic targets | Q38713429 | ||
| Expression and Role of PAICS, a De Novo Purine Biosynthetic Gene in Prostate Cancer | Q38750703 | ||
| PCNA-interacting peptides reduce Akt phosphorylation and TLR-mediated cytokine secretion suggesting a role of PCNA in cellular signaling | Q38896699 | ||
| The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer | Q38914271 | ||
| NUSAP1 expression is upregulated by loss of RB1 in prostate cancer cells | Q38920403 | ||
| Proliferating cell nuclear antigen in neutrophil fate | Q38936561 | ||
| Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer. | Q39108991 | ||
| Forging Ahead through Darkness: PCNA, Still the Principal Conductor at the Replication Fork | Q39117841 | ||
| Clusterin is epigenetically regulated in prostate cancer | Q39958114 | ||
| Transforming growth factor β: A potential biomarker and therapeutic target of ventricular remodeling | Q41593391 | ||
| NUSAP1 promotes invasion and metastasis of prostate cancer | Q42244850 | ||
| Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents | Q47931535 | ||
| EAU guidelines on prostate cancer | Q81404971 | ||
| P4510 | describes a project that uses | limma | Q112236343 |
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | docetaxel | Q420436 |
| P304 | page(s) | 11752-11766 | |
| P577 | publication date | 2018-01-27 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | APIM-peptide targeting PCNA improves the efficacy of docetaxel treatment in the TRAMP mouse model of prostate cancer. | |
| P478 | volume | 9 |
| Q58727488 | "Two hits - one stone"; increased efficacy of cisplatin-based therapies by targeting PCNA's role in both DNA repair and cellular signaling |
| Q60927734 | APIM-Mediated REV3L⁻PCNA Interaction Important for Error Free TLS Over UV-Induced DNA Lesions in Human Cells |
| Q90629773 | Additive effects of a small molecular PCNA inhibitor PCNA-I1S and DNA damaging agents on growth inhibition and DNA damage in prostate and lung cancer cells |
| Q92881732 | Helicase-Like Transcription Factor HLTF and E3 Ubiquitin Ligase SHPRH Confer DNA Damage Tolerance through Direct Interactions with Proliferating Cell Nuclear Antigen (PCNA) |
| Q64117242 | Knockdown of lncRNA MNX1-AS1 suppresses cell proliferation, migration, and invasion in prostate cancer |
| Q92540118 | Targeting the non-canonical roles of PCNA modifies and increases the response to targeted anti-cancer therapy |
| Q98497959 | Ultrasound-Mediated Delivery of Chemotherapy into the Transgenic Adenocarcinoma of the Mouse Prostate Model |
Search more.